Syed Husain, MD
Ophthalmology · Des Moines, IANPI 1760440556
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,575 of the $14,857 with a category attached, or 77.9%. It is spread thinly across 24 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $5,240 and has fallen 65.5% since, to $1,810 in 2025. Among ophthalmology clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 241 payments — averaging $61.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$3K
- Johnson & Johnson Surgical Vision, Inc.$3K
- Alcon$1K
- AbbVie$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
- Bausch & Lomb Americas Inc.$866
- plus $5K from 18 others
What the payments were for
- Consulting fees$2,28215%
- Speaking & faculty fees$1,0007%
- Food & beverage$11,57578%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 19 | $2,958 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $2,564 |
| Alcon | 22 | $1,488 |
| AbbVie(2 entities) | 35 | $1,314 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 40 | $1,021 |
| Bausch & Lomb Americas Inc. | 26 | $866 |
| The Cameron-ehlen Group, Inc. | 9 | $716 |
| Tarsus Pharmaceuticals, Inc. | 19 | $590 |
| NEW World Medical,inc. | 6 | $559 |
| Sun Pharmaceutical Industries Inc. | 14 | $498 |
| Ivantis, Inc | 2 | $312 |
| Sight Sciences, Inc. | 5 | $281 |
| Amgen | 3 | $268 |
| Carl Zeiss Meditec, Inc. | 4 | $230 |
| Oyster Point Pharma, Inc. | 5 | $219 |
| Dompe US, Inc. | 5 | $208 |
| Rxsight Inc | 3 | $202 |
| Aerie Pharmaceuticals, Inc. | 3 | $158 |
| Carl Zeiss Meditec USA, Inc. | 2 | $121 |
| Shire North American Group Inc | 5 | $81 |
| Novartis | 4 | $81 |
| Lumibird Medical Inc. | 1 | $61 |
| Topcon Healthcare Solutions, Inc. | 1 | $47 |
| Kala Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis Symfony IOL$2,132
- iStent$901
- iStent inject W$901
- Tecnis IOL$818
- Photrexa$595
- Kahook Dual Blade$470
- Streamline Surgical System$470
- Ahmed Glaucoma Valve$470
- KXL System$464
- Clareon$441
- Tecnis Simplicity$421
- DURYSTA$352
- iStent Infinite$315
- iDoseTR$315
- Hydrus$312
- HEALON PRO$273
- LUMIGAN$251
- XEN GLAUCOMA TREATMENT SYSTEM$250
- Rocklatan$245
- Rhopressa$245
How this compares
$14,857 in reported general payments places this provider in the 90th percentile of 172 ophthalmology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 50 | $93,641 |
| ProlensaBromfenac Sodium | 150 | $51,447 |
| XiidraLifitegrast | 16 | $16,051 |
| Ofloxacin | 282 | $4,283 |
| Prednisolone Acetate | 40 | $1,825 |
| Latanoprost | 27 | $279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $590 | $93,64150 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $1,021 | $51,447150 claims |
| Bausch & Lomb Americas Inc.Xiidra | $866 | $16,05116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 172 ophthalmology providers in Iowa.
Other ophthalmology in Des Moines
- Christy BensonDes Moines$70K
- Naveen HusainDes Moines$11K
- Reid TurnerDes Moines$7K
- Michael VersackasDes Moines$3K
- Emad ShenoudaDes Moines$3K
- Edward HuHiawatha$160K
- Michael AbramoffIowa City$158K
- Stephen RussellIowa City$137K
- Jared NielsenWest Des Moines$117K
- Matthew RauenWest Des Moines$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.